On December 19, Richard Seeborg, US district judge for the Northern District of California, granted a summary judgment of noninfringement in Amgen v Sandoz.
On December 19, Richard Seeborg, US district judge for the Northern District of California, granted a summary judgment of noninfringement in Amgen v Sandoz.
As Big Molecule Watch reports, biosimilar developer Sandoz had filed a motion for a summary judgment that it did not infringe Amgen’s US Patent 8,940,878 (the ‘878 patent), which covers a method of purifying proteins, when it developed its biosimilar filgrastim and pegfilgrastim molecules.
Amgen claimed that a single step in Sandoz’s process for purifying its filgrastim and pegfilgrastim infringed on claim 7 of its patent, and moved to defer consideration of noninfringement until further discovery on upcoming modifications to Sandoz’s process. Amgen asked the court to wait to make a decision on noninfringement until Sandoz has submitted an application for approval of its modified production process to the FDA (which Sandoz is expected to do in 2018) and produces both its submission and related documents to Amgen.
The court found that Sandoz’s process did not infringe on claim 7, and further denied Amgen’s motion for further discovery, saying that the information Amgen hoped to discover was not material to the finding of noninfringement: “the method claimed by the ’878 patent involves multiple steps and multiple solutions while Sandoz’s accused method involves only one continuous step and only one solution. This substantial difference between the methods will not be altered by the replacement of the current matrix with the new matrix,” according to the ruling.
The summary judgment is further good news for biosimilar developer Sandoz: this week’s legal development follows the federal circuit’s ruling in favor of Sandoz in Amgen v Sandoz, in which the court held that state law cannot compel drug makers to participate in the so-called “patent dance” provided for in the Biologics Price Competition and Innovation Act because state law cannot preempt federal law.
Sandoz, which has already launched its FDA-approved filgrastim biosimilar (Zarxio) in the United States, suffered a regulatory setback with its pegfilgrastim in 2016 when the FDA issued the biosimilar developer a complete response letter. However, Sandoz recently released news results from a phase 1 clinical trial of its proposed pegfilgrastim biosimilar, LA-EP2006, showing that its product matched Amgen’s reference Neulasta in terms of safety, pharmacokinetics, pharmacodynamics, and immunogenicity in healthy subjects, and the proposed biosimilar is currently under review by the European Medicines Agency.
BioRationality: EMA Accepts Waiver of Clinical Efficacy Testing of Biosimilars
April 21st 2025Sarfaraz K. Niazi, PhD, shares his latest citizen's petition to the FDA, calling on the agency to waive clinical efficacy testing in response to the European Medicines Agency's (EMA) efforts towards the same goal.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
How State Substitution Laws Shape Insulin Biosimilar Adoption
April 15th 2025States with fewer restrictions on biosimilar substitution tend to see higher uptake of interchangeable insulin glargine, showing how even small policy details can significantly influence biosimilar adoption and expand access to more affordable insulin.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
BioRationality: Commemorating the 15th Anniversary of the BPCIA
April 8th 2025Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical testing, and enhancing FDA-led education to counter stakeholder misconceptions are key recommendations put forth in this opinion piece by Sarfaraz K. Niazi, PhD.